Project Grant R01CA306891
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a Project Grant of $640,135 under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025 through July 31, 2030. This award supports the development of next-generation menin inhibitors designed to overcome clinical resistance observed in acute myeloid leukemia (AML) patients treated with current menin-mixed lineage leukemia 1 (MLL1) inhibitors. The...
- Federal Grant Award Summary The University of Michigan received a $2.82 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 6, 2025, with a completion date of July 31, 2029. The project focuses on developing new methodologies to measure and interrupt metabolic fluxes in glioblastomas (GBMs), highly aggressive brain cancers that currently lack effective treatment strategies despite standard resection, radiation, and...
- Federal Grant Award Summary The University of Michigan's Regents, through its Office of Research and Sponsored Projects, received a $319,505 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2030. This award funds the development and delivery of comprehensive training in methodologies for adapting and personalizing cancer control interventions across the continuum of care—including cancer risk...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $139,968 under the Cancer Research Manpower program (CFDA 93.398) on July 15, 2025, for a project period extending through June 30, 2027. This Project Grant supports biomedical research training and cancer-related research in basic and translational science aligned with the National Cancer Program priorities. The award funds a research initiative titled "Beyond Lysis:...
- Federal Project Grant Award Summary The University of Michigan's Office of Research and Sponsored Projects received a Project Grant of $101,340 awarded on December 12, 2025, by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398). This award supports research investigating the role of membrane-spanning 4A member MS4A14 in anti-tumor immunity, with the project extending through June 16, 2028. The research focuses on understanding how MS4A14, a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $136,412 to the Regents of the University of Michigan, effective August 1, 2025 through July 31, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at defining and interrupting metabolic crosstalk in the glioblastoma microenvironment. The research builds upon preliminary findings demonstrating that glioblastoma (GBM) tumors acquire nutrients through...
- Federal Project Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a Project Grant totaling $2,864,671 on September 10, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by enteric bacteria associated with colorectal cancer (CRC). The research centers on two primary deliverables: (1) engineering...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.28M Project Grant effective September 1, 2025, through August 31, 2029, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds the DEEPSRH (Transforming Molecular Cancer Screening with Stimulated Raman Histology and Deep Neural Networks) initiative, which addresses barriers to molecular cancer testing by developing innovative screening and...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.84 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Maryland, Baltimore, with a performance period from August 18, 2025, through July 30, 2029. This research initiative aims to develop and optimize novel dual-activation compounds that enhance the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens used to treat triple-negative...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a Project Grant of $162,305 to the Regents of the University of Michigan, with an award date of August 1, 2025 and completion date of July 31, 2030. This award supports a mentored research training project led by Dr. Peggy Hsu, MD, PhD, a physician-scientist developing expertise in early detection and characterization of anaplastic lymphoma kinase...
The University of Michigan's Regents received a $646,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 11, 2026 through February 28, 2031. This award supports research into novel multi-targeted therapeutic strategies for T-cell lymphomas (TCL) that are chemotherapy-resistant and refractory to existing targeted agents. The research addresses the multifactorial mechanisms underlying treatment failure in TCL, including high-risk genetic landscapes, oncogenic transcriptional activation, and the creation of lymphomagenic niches within the tumor microenvironment. The project specifically investigates the crosstalk between cell-autonomous oncogenic mechanisms and tumor microenvironment constituents—particularly lymphoma-associated macrophages—to develop improved combination therapeutic approaches that simultaneously target malignant T cells and their supportive microenvironment. The deliverables from this research initiative include the identification and preclinical/clinical validation of novel multi-targeted therapeutic strategies designed to improve survival outcomes in high-risk and chemorefractory TCL patients. Through mechanistic research and translational studies conducted at the University of Michigan's Ann Arbor campus, the project will generate foundational knowledge and therapeutic targets that inform clinical trial development and expand treatment options beyond current standard-of-care approaches for this patient population with historically dismal outcomes.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $646.9k | 3/11/26 |